Medline (MDLN) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Medline (MDLN) stock.

Latest Upgrades and Downgrades for Medline Stock

Date	Firm	Analyst	Action	Rating Change	Price Target
—	UBS	Kevin Caliendo	PT Raise	Buy	$43→$49
—	Citigroup	Joanne Wuensch	PT Raise	Buy	$45→$47
—	Leerink Partners	Michael Cherny	PT Raise	Outperform	$43→$46
—	Evercore ISI Group	Elizabeth Anderson	PT Raise	Outperform	$38→$44
—	BTIG	David Larsen	Maintained	Buy	$55
—	Mizuho	Steven Valiquette	PT Cut	Outperform	$48→$45
—	Barclays	Glen Santangelo	PT Cut	Overweight	$45→$43
—	UBS	Kevin Caliendo	PT Cut	Buy	$45→$43
—	BTIG	David Larsen	Maintained	Buy	$55
—	JP Morgan	Lisa Gill	PT Cut	Overweight	$53→$46
—	Tigress Financial	Ivan Feinseth	PT Cut	Buy	$62→$55
—	Wells Fargo	Stephen Baxter	PT Cut	Equal-Weight	$45→$34
—	TD Cowen	Charles Rhyee	PT Cut	Buy	$53→$45
—	RBC Capital	Ryan Halsted	PT Cut	Outperform	$53→$46
—	Truist Securities	Jailendra Singh	PT Cut	Buy	$56→$47
—	Evercore ISI Group	Elizabeth Anderson	PT Cut	Outperform	$48→$39
—	Stifel	Rick Wise	PT Cut	Buy	$50→$45
—	BTIG	David Larsen	Maintained	Buy	$55
—	Baird	Eric Coldwell	PT Cut	Outperform	$57→$45
—	Barclays	Glen Santangelo	PT Cut	Overweight	$50→$45

Analyst Ratings News

PRO
UBS Maintains Buy on Medline, Raises Price Target to $49

UBS analyst Kevin Caliendo maintains Medline (NASDAQ:MDLN) with a Buy and raises the price target from $43 to $49.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Medline, Raises Price Target to $47

Citigroup analyst Joanne Wuensch maintains Medline (NASDAQ:MDLN) with a Buy and raises the price target from $45 to $47.

Benzinga Newsdesk

PRO
Leerink Partners Maintains Outperform on Medline, Raises Price Target to $46

Leerink Partners analyst Michael Cherny maintains Medline (NASDAQ:MDLN) with a Outperform and raises the price target from $43 to $46.

Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on Medline, Raises Price Target to $44

Evercore ISI Group analyst Elizabeth Anderson maintains Medline (NASDAQ:MDLN) with a Outperform and raises the price target from $38 to $44.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Medline, Maintains $55 Price Target

BTIG analyst David Larsen reiterates Medline (NASDAQ:MDLN) with a Buy and maintains $55 price target.

Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Medline, Lowers Price Target to $45

Mizuho analyst Steven Valiquette maintains Medline (NASDAQ:MDLN) with a Outperform and lowers the price target from $48 to $45.

Benzinga Newsdesk

Medline Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Medline (MDLN) Stock Price Target 2026

Latest Upgrades and Downgrades for Medline Stock

Medline (MDLN) Stock Price Target 2026

Latest Upgrades and Downgrades for Medline Stock

Analyst Ratings News

PRO
UBS Maintains Buy on Medline, Raises Price Target to $49

PRO
Citigroup Maintains Buy on Medline, Raises Price Target to $47

PRO
Leerink Partners Maintains Outperform on Medline, Raises Price Target to $46

PRO
Evercore ISI Group Maintains Outperform on Medline, Raises Price Target to $44

PRO
BTIG Reiterates Buy on Medline, Maintains $55 Price Target

PRO
Mizuho Maintains Outperform on Medline, Lowers Price Target to $45

People Also Watch

People Also Watch

Analyst Ratings News

PRO
UBS Maintains Buy on Medline, Raises Price Target to $49

PRO
Citigroup Maintains Buy on Medline, Raises Price Target to $47

PRO
Leerink Partners Maintains Outperform on Medline, Raises Price Target to $46

PRO
Evercore ISI Group Maintains Outperform on Medline, Raises Price Target to $44

PRO
BTIG Reiterates Buy on Medline, Maintains $55 Price Target

PRO
Mizuho Maintains Outperform on Medline, Lowers Price Target to $45

Medline Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Medline (MDLN) Stock Price Target 2026

Latest Upgrades and Downgrades for Medline Stock

Medline (MDLN) Stock Price Target 2026

Latest Upgrades and Downgrades for Medline Stock

Analyst Ratings News

PROUBS Maintains Buy on Medline, Raises Price Target to $49

PROCitigroup Maintains Buy on Medline, Raises Price Target to $47

PROLeerink Partners Maintains Outperform on Medline, Raises Price Target to $46

PROEvercore ISI Group Maintains Outperform on Medline, Raises Price Target to $44

PROBTIG Reiterates Buy on Medline, Maintains $55 Price Target

PROMizuho Maintains Outperform on Medline, Lowers Price Target to $45

People Also Watch

People Also Watch

Analyst Ratings News

PROUBS Maintains Buy on Medline, Raises Price Target to $49

PROCitigroup Maintains Buy on Medline, Raises Price Target to $47

PROLeerink Partners Maintains Outperform on Medline, Raises Price Target to $46

PROEvercore ISI Group Maintains Outperform on Medline, Raises Price Target to $44

PROBTIG Reiterates Buy on Medline, Maintains $55 Price Target

PROMizuho Maintains Outperform on Medline, Lowers Price Target to $45

PRO
UBS Maintains Buy on Medline, Raises Price Target to $49

PRO
Citigroup Maintains Buy on Medline, Raises Price Target to $47

PRO
Leerink Partners Maintains Outperform on Medline, Raises Price Target to $46

PRO
Evercore ISI Group Maintains Outperform on Medline, Raises Price Target to $44

PRO
BTIG Reiterates Buy on Medline, Maintains $55 Price Target

PRO
Mizuho Maintains Outperform on Medline, Lowers Price Target to $45

PRO
UBS Maintains Buy on Medline, Raises Price Target to $49

PRO
Citigroup Maintains Buy on Medline, Raises Price Target to $47

PRO
Leerink Partners Maintains Outperform on Medline, Raises Price Target to $46

PRO
Evercore ISI Group Maintains Outperform on Medline, Raises Price Target to $44

PRO
BTIG Reiterates Buy on Medline, Maintains $55 Price Target

PRO
Mizuho Maintains Outperform on Medline, Lowers Price Target to $45